Incyte (INCY)
126.75
-1.25 (0.98%)
Upcoming Events
Latest Headlines
Incyte to Present at Upcoming Investor Conferences
September 1, 2026 8:00 AM - BizWire
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
September 1, 2026 7:12 AM - StreetInsider
BMO Capital Reiterates Market Perform Rating on Incyte (INCY)
September 1, 2026 4:02 AM - StreetInsider
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
August 27, 2026 6:00 PM - Globe NewsWire
Form 4 INCYTE CORP For: Aug 25 Filed by: Basi Ramitpal K
August 27, 2026 4:07 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
August 27, 2026 7:06 AM - StreetInsider
TD Cowen Assumes Incyte (INCY) at Buy
August 22, 2026 7:54 AM - StreetInsider
Form 4 INCYTE CORP For: Aug 19 Filed by: CAGNONI PABLO J
August 20, 2026 5:15 PM - SEC Filing
Canaccord Starts Incyte (INCY) at Buy
August 20, 2026 7:16 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
August 20, 2026 6:52 AM - StreetInsider
Form 144 INCYTE CORP Filed by: CAGNONI PABLO J
August 19, 2026 4:20 PM - SEC Filing
Incyte (INCY) PT Raised to $130 at Piper Sandler
August 17, 2026 7:43 AM - StreetInsider
Form 4 INCYTE CORP For: Aug 12 Filed by: CAGNONI PABLO J
August 14, 2026 4:03 PM - SEC Filing
Form 144 INCYTE CORP Filed by: CAGNONI PABLO J
August 12, 2026 4:09 PM - SEC Filing
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026 4:30 PM - BizWire
Form 4 INCYTE CORP For: Aug 05 Filed by: CAGNONI PABLO J
August 7, 2026 4:04 PM - SEC Filing
Form 4 INCYTE CORP For: Aug 05 Filed by: Mayes Patrick A
August 7, 2026 4:03 PM - SEC Filing
Form 144 INCYTE CORP Filed by: CAGNONI PABLO J
August 5, 2026 4:19 PM - SEC Filing
Form 144 INCYTE CORP Filed by: Mayes Patrick A
August 5, 2026 4:18 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 31 Filed by: CAGNONI PABLO J
August 4, 2026 4:04 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 31 Filed by: Mayes Patrick A
August 4, 2026 4:04 PM - SEC Filing
Incyte (INCY) PT Raised to $137 at Mizuho
August 4, 2026 6:39 AM - StreetInsider
Form 144 INCYTE CORP Filed by: Mayes Patrick A
August 3, 2026 4:40 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
August 3, 2026 6:54 AM - StreetInsider
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
August 2, 2026 10:01 AM - PR NewsWire
Form 144 INCYTE CORP Filed by: Mayes Patrick A
July 31, 2026 5:00 PM - SEC Filing
Form 144 INCYTE CORP Filed by: CAGNONI PABLO J
July 31, 2026 4:05 PM - SEC Filing
Incyte (INCY) PT Raised to $120 at JPMorgan
July 30, 2026 9:02 AM - StreetInsider
Incyte (INCY) PT Raised to $119 at Morgan Stanley
July 29, 2026 8:55 AM - StreetInsider
Incyte (INCY) PT Raised to $116 at Wells Fargo
July 29, 2026 8:13 AM - StreetInsider
Incyte (INCY) PT Raised to $130 at BMO Capital
July 29, 2026 7:14 AM - StreetInsider
Incyte (INCY) PT Raised to $150 at Guggenheim
July 29, 2026 7:14 AM - StreetInsider
Incyte (INCY) PT Raised to $150 at H.C. Wainwright
July 29, 2026 6:48 AM - StreetInsider
Incyte (INCY) PT Raised to $109 at RBC Capital
July 29, 2026 6:21 AM - StreetInsider
EU approves Incyte's Opzelura cream for moderate atopic dermatitis
July 29, 2026 6:01 AM - StreetInsider
Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
July 29, 2026 6:00 AM - BizWire
Incyte (INCY) PT Raised to $139 at Barclays
July 29, 2026 5:20 AM - StreetInsider
Form 10-Q INCYTE CORP For: Jun 30
July 28, 2026 4:02 PM - SEC Filing
Incyte (INCY) PT Raised to $120 at Oppenheimer
July 28, 2026 1:38 PM - StreetInsider
Incyte (INCY) Tops Q2 EPS by 110c ; Offers Guidance
July 28, 2026 7:04 AM - StreetInsider
Form 8-K INCYTE CORP For: Jul 28
July 28, 2026 7:02 AM - SEC Filing
Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates
July 28, 2026 7:00 AM - BizWire
Form 4 INCYTE CORP For: Jul 23 Filed by: Morrissey Michael James
July 27, 2026 6:24 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 23 Filed by: Heeson Lee
July 27, 2026 6:23 PM - SEC Filing
Incyte (INCY) PT Raised to $104 at Morgan Stanley
July 23, 2026 8:43 AM - StreetInsider
Incyte (INCY) PT Raised to $110 at JPMorgan
July 23, 2026 7:39 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
July 21, 2026 6:51 AM - StreetInsider
Form 4 INCYTE CORP For: Jul 16 Filed by: Tray Thomas
July 20, 2026 4:11 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Stein Steven H
July 20, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Mayes Patrick A
July 20, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: CAGNONI PABLO J
July 20, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Issa Mohamed Khairie
July 20, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Basi Ramitpal K
July 20, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Gardner David H
July 20, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Hoffman Richard A.
July 20, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 16 Filed by: Meury William
July 20, 2026 4:08 PM - SEC Filing
Halozyme and Incyte sign drug delivery licensing agreement
July 20, 2026 8:00 AM - StreetInsider
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
July 20, 2026 8:00 AM - PR NewsWire
Incyte to present six oncology studies at ESMO Congress 2026
July 17, 2026 1:11 PM - StreetInsider
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
July 17, 2026 1:10 PM - BizWire
Form 144 INCYTE CORP Filed by: Stein Steven H
July 16, 2026 4:16 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: CAGNONI PABLO J
July 16, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: Mayes Patrick A
July 16, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: Tray Thomas
July 16, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 14 Filed by: Stein Steven H
July 16, 2026 4:07 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 15 Filed by: Issa Mohamed Khairie
July 16, 2026 4:07 PM - SEC Filing
Form 144 INCYTE CORP Filed by: Issa Mohamed Khairie
July 16, 2026 4:05 PM - SEC Filing
Form 144 INCYTE CORP Filed by: Stein Steven H
July 15, 2026 4:10 PM - SEC Filing
Incyte (INCY) Reiterated at Market Perform by Citizens on Updated VIVID-3 Data
July 15, 2026 4:37 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
July 14, 2026 6:57 AM - StreetInsider
Incyte (INCY) PT Raised to $134 at Barclays
July 14, 2026 5:12 AM - StreetInsider
Incyte (INCY) PT Raised to $112 at BMO Capital
July 13, 2026 7:33 AM - StreetInsider
Incyte reports 81% bleed reduction in VWD drug trial data
July 13, 2026 4:00 AM - StreetInsider
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
July 13, 2026 4:00 AM - BizWire
Incyte to Report Second Quarter Financial Results
July 8, 2026 8:00 AM - BizWire
Form 4 INCYTE CORP For: Jul 02 Filed by: Mayes Patrick A
July 7, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 02 Filed by: Tray Thomas
July 7, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 02 Filed by: Meury William
July 7, 2026 4:10 PM - SEC Filing
Form 4 INCYTE CORP For: Jul 02 Filed by: Stein Steven H
July 7, 2026 4:09 PM - SEC Filing
Incyte (INCY) PT Raised to $99 at RBC Capital
July 7, 2026 7:55 AM - StreetInsider
Form 8-K INCYTE CORP For: Jul 06
July 6, 2026 4:06 PM - SEC Filing
Incyte acquires Vega Therapeutics for $1.25B upfront
July 6, 2026 8:39 AM - StreetInsider
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
July 6, 2026 8:39 AM - BizWire
Form 4 INCYTE CORP For: Jun 30 Filed by: Baker Brothers Life Sciences LP
July 2, 2026 4:33 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 30 Filed by: Clancy Paul J
July 2, 2026 4:09 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 30 Filed by: HARRIGAN EDMUND
July 2, 2026 4:08 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
June 29, 2026 7:10 AM - StreetInsider
Star Therapeutics to present VGA039 trial data at ISTH 2026
June 26, 2026 9:00 AM - StreetInsider
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
June 26, 2026 9:00 AM - BizWire
Incyte's ruxolitinib cream gets positive EU review for eczema
June 26, 2026 7:30 AM - StreetInsider
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
June 26, 2026 7:30 AM - BizWire
Incyte (INCY) PT Raised to $113 at UBS
June 26, 2026 7:07 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
June 24, 2026 6:43 AM - StreetInsider
Incyte (INCY) PT Raised to $105 at Truist Securities
June 22, 2026 1:25 PM - StreetInsider
Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
June 22, 2026 7:53 AM - StreetInsider
Form 8-K INCYTE CORP For: Jun 22
June 22, 2026 7:01 AM - SEC Filing
BMO Capital Upgrades Incyte (INCY) to Market Perform
June 22, 2026 4:19 AM - StreetInsider
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
June 19, 2026 2:01 AM - BizWire
BMO Capital on Incyte (INCY): ''989 Updates Provide More Context to ET/MF Opportunity'
June 15, 2026 10:10 AM - StreetInsider
Stifel Reiterates Buy Rating on Incyte (INCY)
June 15, 2026 9:24 AM - StreetInsider
Mirum and Incyte report positive phase 2 results for FOP treatment
June 14, 2026 4:35 PM - StreetInsider
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
June 14, 2026 4:35 PM - BizWire
NASDAQ: INCY shows 25% reduction in disease progression risk in lymphoma study
June 13, 2026 6:01 AM - StreetInsider
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
June 13, 2026 6:01 AM - BizWire
Form 4 INCYTE CORP For: Jun 08 Filed by: BAKER BROS. ADVISORS LP
June 10, 2026 4:41 PM - SEC Filing
Incyte (INCY) PT Raised to $136 at Guggenheim
June 10, 2026 4:39 PM - StreetInsider
Form 4 INCYTE CORP For: Jun 08 Filed by: HARRIGAN EDMUND
June 10, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: Clancy Paul J
June 10, 2026 4:08 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: FOUSE JACQUALYN A
June 10, 2026 4:07 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: BIENAIME JEAN JACQUES
June 10, 2026 4:06 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: High Katherine A
June 10, 2026 4:06 PM - SEC Filing
Form 4 INCYTE CORP For: Jun 08 Filed by: BRAWLEY OTIS W
June 10, 2026 4:06 PM - SEC Filing
Incyte (INCY) PT Raised to $140 at H.C. Wainwright
June 10, 2026 7:11 AM - StreetInsider
Form 8-K INCYTE CORP For: Jun 08
June 9, 2026 4:07 PM - SEC Filing
Stifel Reiterates Buy Rating on Incyte (INCY)
June 9, 2026 9:11 AM - StreetInsider
Full Article List
